MD Anderson Partners with Merck to Develop Keytruda as Mono- and Combined Therapy
News
The University of Texas MD Anderson Cancer Center, together with Merck, will be evaluating the latter’s anti-PD-1 treatment, Keytruda (pembrolizumab), when administered in combination with other anti-cancer therapies, such as ... Read more